Immune response and reactogenicity of an unadjuvanted intradermally delivered human papillomavirus vaccine using a first generation Nanopatch™ in rhesus macaques: An exploratory, pre-clinical feasibility assessment

The human papillomavirus (HPV) 9-valent, recombinant vaccine (Gardasil™9) helps protect young adults (males and females) against anogenital cancers and genital warts caused by certain HPV genotypes (ref. Gardasil™9 insert). This vaccine is administered intramuscularly (IM). The aim of this study was...

Descripción completa

Detalles Bibliográficos
Autores principales: Meyer, Brian K., Kendall, Mark A.F., Williams, Donna M., Bett, Andrew J., Dubey, Sheri, Gentzel, Renee C., Casimiro, Danilo, Forster, Angus, Corbett, Holly, Crichton, Michael, Baker, S. Ben, Evans, Robert K., Bhambhani, Akhilesh
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2019
Materias:
Regular paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6668242/
https://www.ncbi.nlm.nih.gov/pubmed/31384745
http://dx.doi.org/10.1016/j.jvacx.2019.100030

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6668242/
https://www.ncbi.nlm.nih.gov/pubmed/31384745
http://dx.doi.org/10.1016/j.jvacx.2019.100030

Ejemplares similares